Overview
Syllabus
Intro
Learning Objectives
Spinal Muscular Atrophy (1891-1892)
Spinal Muscular Atrophy (Type 1)
SMA Incidence and Prevalence Are Different
Age of Onset Classification (Munsat et al. MDA, 1992)
FUNCTIONAL CLASSIFICATION Continuum of severity-Phenotypic spectrum
Discovery of SMN1 gene
SMN Protein Function?
SMA Type & SMN2 Copy Number
Autosomal Recessive Inheritance
5% SMA"Non-carrier" Parents?
Carrier Frequency of 5 SMA
SMA Therapeutics
Therapeutic Strategies for SMA
SMA Clinical Trials Anti-Sense Oligos (ASO)
Nusinersin/Spinraza: Modulating Splicing of SMN2 to Increase Normal SMN Protein
Nusinersin/Spinraza Studies
Spinraza - 1st SMA Treatment
Spinraza at BCH
Gene Therapy at BCH
SMA Drug Pipeline
PTC-Roche Pharmaceuticals: Oral SMN2 splicing modifier
SMA Carrier Screening
New Born Screening for SMA
SMA Patient Care
In normal infants, motor units are established postnatally They are lost early and precipitously in patients with SMA
Use of Multiple Therapies
Thank you!
Taught by
Ambry Genetics